Theory Paper IDrNB Cardiology – Theory Notes
DRUG INTERACTIONS: MECHANISMS & EXAMPLES
IINTRODUCTION AND CLASSIFICATION
- Definition: A drug-drug (or drug-food/herb) interaction occurs when the pharmacological disposition or clinical effect of one medication is quantitatively or qualitatively altered by the prior or concurrent administration of another agent.
- Clinical Impact in Cardiology: Because core cardiovascular medications—including Vitamin K Antagonists (Warfarin), Direct Oral Anticoagulants (DOACs), Digoxin, Antiarrhythmic Drugs (AADs), and Calcineurin Inhibitors (in heart transplant recipients)—possess narrow therapeutic indices and steep dose-response curves, interactions are a leading preventable cause of fatal arrhythmia, major hemorrhage, thromboembolism, and rhabdomyolysis.
- Mechanistic Classification: Divided into Pharmacokinetic (PK) Interactions (altering drug Absorption, Distribution, Metabolism, or Excretion [ADME] and thereby changing plasma drug concentrations) and Pharmacodynamic (PD) Interactions (additive, synergistic, or antagonistic effects at the target receptor, ion channel, or physiological system without altering plasma drug levels).
IIPHARMACOKINETIC (PK) INTERACTIONS: THE ADME PATHWAYS
AAbsorption Interactions (Gastrointestinal Tract)
- Intraluminal Chelation: Bile acid sequestrants (Cholestyramine, Colestipol, Colesevelam) bind anionic and lipophilic cardiovascular drugs—specifically Digoxin, Warfarin, Statins, Ezetimibe, Amiodarone, and Thiazide/Loop Diuretics—in the intestinal lumen, reducing bioavailability; medications must be administered 1 hour before or 4 to 6 hours after the resin.
- Gastric pH and Gut Microbiome: Proton pump inhibitors (PPIs) lower gastric acidity, reducing the absorption of weakly basic drugs (Dabigatran absorption decreases by 20 to 30 percent, though clinically non-significant), while broad-spectrum oral antibiotics (Macrolides, Tetracyclines) eradicate gut Eggerthella lenta (formerly Eubacterium lentum) (which normally inactivates digoxin) and vitamin K-producing flora, potentiating Digoxin toxicity and Warfarin over-anticoagulation.
BHepatic Metabolism Interactions (The Cytochrome P450 System)
- CYP3A4 Inhibition (Statin Myopathy & Rhabdomyolysis): Simvastatin and Lovastatin (and to a lesser extent Atorvastatin) are extensively metabolized by hepatic and intestinal CYP3A4 (whereas Rosuvastatin, Pravastatin, Pitavastatin, and Fluvastatin have minimal CYP3A4 metabolism). Potent CYP3A4 inhibitors—including Macrolides (Clarithromycin, Erythromycin), Azole Antifungals (Itraconazole, Ketoconazole, Posaconazole), HIV/HCV Protease Inhibitors (Ritonavir), Cyclosporine, and moderate inhibitors like Amiodarone, Verapamil, Diltiazem, Amlodipine, and Ranolazine—markedly elevate statin plasma AUC, precipitating severe statin-associated myopathy and fatal rhabdomyolysis. (FDA mandate: do not exceed Simvastatin 10 mg/day with Verapamil/Diltiazem, or 20 mg/day with Amiodarone, Amlodipine, or Ranolazine.)
- CYP2C9 Inhibition (Warfarin Bleeding Risk): The more potent S-enantiomer of Warfarin is metabolized by CYP2C9 (while R-warfarin is metabolized by CYP1A2/CYP3A4). Amiodarone, Fluconazole, Metronidazole, Trimethoprim-Sulfamethoxazole, and Fluvastatin potently inhibit CYP2C9, causing rapid INR surges and major hemorrhage; empirically reduce the Warfarin dose by 30 to 50 percent when starting Amiodarone.
- CYP2C19 Inhibition (Clopidogrel Prodrug Failure): Clopidogrel is an inactive prodrug requiring two-step hepatic bioactivation predominantly via CYP2C19. Omeprazole and Esomeprazole competitively inhibit CYP2C19, attenuating platelet inhibition on ex vivo assays (though the randomized COGENT Trial showed reduced GI bleeding without a significant clinical spike in MACE; nevertheless, guidelines recommend preferring Pantoprazole or Rabeprazole, which have minimal CYP2C19 inhibition, when a PPI is co-prescribed with Clopidogrel).
- Strong CYP3A4 / P-gp Induction (Therapeutic Failure): Rifampicin, Phenytoin, Carbamazepine, Phenobarbital, and St. John’s Wort strongly induce both CYP3A4 and P-glycoprotein, accelerating the clearance of all DOACs (Dabigatran, Rivaroxaban, Apixaban, Edoxaban), Ticagrelor, Warfarin, and Calcium Channel Blockers, precipitating ischemic stroke or stent thrombosis (Class III — Contraindicated with DOACs and Ticagrelor).
CEfflux Transporter Interactions (P-Glycoprotein [P-gp] & OATP1B1)
- P-gp Inhibition and Digoxin Toxicity: Digoxin is cleared unchanged by the kidneys via glomerular filtration and active tubular secretion mediated by the P-glycoprotein (P-gp / ABCB1) efflux pump. Amiodarone, Dronedarone, Verapamil, Quinidine, Propafenone, Clarithromycin, Itraconazole, Cyclosporine, and Ranolazine inhibit P-gp (reducing both renal and extrarenal clearance) and increase serum digoxin concentrations by 50 to 100 percent, precipitating bidirectional VT or AV block. Mandatory Rule: Reduce the Digoxin dose by 50 percent (or discontinue) when initiating Amiodarone, Dronedarone, Verapamil, or Quinidine.
- OATP1B1 Inhibition: Cyclosporine and Gemfibrozil strongly inhibit the hepatic uptake transporter OATP1B1 (and glucuronidation), multiplying levels of all statins (including Rosuvastatin and Pravastatin); Gemfibrozil + Statin is strictly contraindicated (use Fenofibrate if fibrate therapy is required).
IIIPHARMACODYNAMIC (PD) INTERACTIONS: RECEPTOR AND CHANNEL OVERLAP
- Synergistic cGMP Vasodilation (Nitrates / Riociguat + PDE-5 Inhibitors — Class III): Organic Nitrates (nitroglycerin, isosorbide dinitrate/mononitrate, nicorandil) increase nitric oxide-mediated cyclic GMP (cGMP) synthesis, while Soluble Guanylate Cyclase (sGC) stimulators (Riociguat, Vericiguat) directly stimulate cGMP synthesis, and PDE-5 Inhibitors (Sildenafil, Tadalafil, Vardenafil) block cGMP degradation. Co-administration causes an unopposed intracellular cGMP surge and profound, refractory, potentially fatal systemic hypotension. Nitrates are strictly contraindicated within 24 hours of Sildenafil/Vardenafil and within 48 hours of Tadalafil (and Riociguat is contraindicated with both nitrates and PDE-5 inhibitors).
- Additive Sinoatrial and AV Nodal Suppression: Combining Beta-Blockers with Non-Dihydropyridine Calcium Channel Blockers (Verapamil or Diltiazem), Digoxin, Ivabradine (note: Verapamil/Diltiazem also inhibit CYP3A4 metabolism of Ivabradine and are strictly contraindicated with Ivabradine), or Amiodarone produces synergistic negative chronotropic, dromotropic, and inotropic effects, precipitating severe sinus bradycardia, complete heart block, or cardiogenic shock.
- RAAS Blockade + NSAIDs (“Triple Whammy” Nephrotoxicity and Hyperkalemia): NSAIDs and COX-2 inhibitors block renal vasodilatory prostaglandin synthesis, constricting the afferent glomerular arteriole, while ACE Inhibitors / ARBs / ARNI dilate the efferent arteriole and Loop/Thiazide Diuretics reduce intravascular volume—precipitating acute kidney injury, sodium retention, blunted diuretic response, and acute decompensated heart failure. Furthermore, combining ACEi + ARB (ONTARGET trial) or ACEi/ARB/ARNI + MRA (Spironolactone/Eplerenone) + Potassium supplements/Trimethoprim causes life-threatening hyperkalemia (ACEi within 36 hours of Sacubitril/Valsartan is Class III contraindicated due to synergistic bradykinin accumulation and angioedema).
- Synergistic IKr (hERG) Blockade and Torsades de Pointes: Combining Class IA (Quinidine, Procainamide, Disopyramide) or Class III (Sotalol, Dofetilide, Ibutilide, Amiodarone) antiarrhythmics with non-cardiac QT-prolonging drugs—Macrolides (Erythromycin, Clarithromycin, Azithromycin), Fluoroquinolones (Moxifloxacin, Levofloxacin), Azole Antifungals (Fluconazole), Antiemetics (Ondansetron, Domperidone), Antipsychotics (Haloperidol), or Methadone—causes additive blockade of the rapid delayed rectifier potassium current (IKr), prolonging QTc (>500 ms) and triggering early afterdepolarizations and Torsades de Pointes (TdP).
| Interacting Drug Pair | Primary Mechanism (PK vs. PD) | Clinical Consequence & Mandatory Action |
|---|---|---|
| Nitrates / Riociguat + Sildenafil / Tadalafil | PD: Synergistic intracellular cGMP accumulation | Fatal refractory hypotension; wait >=24 h (Sildenafil) or >=48 h (Tadalafil) (Class III) |
| Sacubitril/Valsartan (ARNI) + ACE Inhibitor | PD: Dual inhibition of bradykinin degradation (neprilysin + ACE) | Life-threatening angioedema; mandatory 36-hour washout of ACEi before ARNI (Class III) |
| Amiodarone / Verapamil + Digoxin | PK: Inhibition of renal/intestinal P-gp efflux pump (+ PD AV block) | Doubles serum Digoxin level -> bidirectional VT/AV block; cut Digoxin dose by 50% |
| Simvastatin / Lovastatin + Clarithromycin / Ritonavir / Gemfibrozil | PK: Potent CYP3A4 or OATP1B1 inhibition | Massive statin surge -> Rhabdomyolysis; contraindicated (hold statin or use Pravastatin/Rosuvastatin) |
| DOACs + Dronedarone / Rifampicin | PK: Dual P-gp + CYP3A4 inhibition (Dronedarone) or induction (Rifampicin) | Major bleeding (Dronedarone + Dabigatran/Rivaroxaban) or stroke (Rifampicin + any DOAC) (Class III) |
| Sotalol / Amiodarone + Macrolides / Fluconazole | PD (+ PK): Additive hERG (IKr) K+ channel block | Marked QTc prolongation -> Torsades de Pointes (TdP) |
IVCONTEMPORARY GUIDELINE FOCUS: DOACs AND RITONAVIR (EHRA 2021 / ESC 2024 AF GUIDELINES)
- DOACs and Antiarrhythmic Drugs (EHRA Practical Guide): All four DOACs (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) are substrates of the P-gp efflux transporter, and Rivaroxaban and Apixaban also undergo hepatic CYP3A4 metabolism (~18% and ~25%, respectively):
- Dronedarone (Strong P-gp + Moderate CYP3A4 Inhibitor): Contraindicated with Dabigatran and Rivaroxaban; requires 50 percent dose reduction of Edoxaban (to 30 mg OD) and caution with Apixaban.
- Verapamil: Increases Dabigatran levels; reduce Dabigatran to 110 mg BD when co-administered with Verapamil.
- Amiodarone: Mildly increases DOAC plasma levels (12 to 60 percent); no routine DOAC dose reduction is required unless concomitant renal/weight/age dose-reduction criteria are met.
- Nirmatrelvir/Ritonavir (Paxlovid) Interactions: Ritonavir is an irreversible, ultra-potent CYP3A4 and P-gp inhibitor. Co-administration is strictly contraindicated with Amiodarone, Flecainide, Propafenone, Dronedarone, Quinidine, Ranolazine, Ivabradine, Eplerenone, Sildenafil (for PAH), Ticagrelor, Rivaroxaban, Dabigatran (in renal impairment), Simvastatin, and Lovastatin (whereas Prasugrel or Aspirin is safer than Clopidogrel/Ticagrelor, and Atorvastatin/Rosuvastatin should be temporarily held during the 5-day course).
VPRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT
- Rifampicin Anti-Tubercular Therapy (ATT) Clashes: Because tuberculosis is endemic in India, cardiac patients frequently require Rifampicin-based ATT. Rifampicin is a potent pan-inducer of CYP3A4, CYP2C9, CYP2C19, and P-gp, rendering all DOACs, Ticagrelor, Ivabradine, Ranolazine, and most Calcium Channel Blockers ineffective and requiring 2- to 3-fold higher doses of Warfarin with meticulous weekly INR monitoring (and urgent Warfarin dose reduction when ATT is stopped to prevent fatal rebound hemorrhage).
- Irrational Fixed-Dose Combinations (FDCs) and Polypharmacy: Widespread prescription of multi-drug FDCs (such as Statin + Fenofibrate or Aspirin + Clopidogrel + Atorvastatin) and unmonitored over-the-counter NSAID or herbal/Ayurvedic consumption in patients with diabetic nephropathy frequently precipitates acute-on-chronic kidney injury, hyperkalemia, and upper GI bleeding.
Key references
- Steffel J, Collins R, Antz M, et al.: 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation, EP Europace, 2021.
- Van Gelder IC, Rienstra M, Bunting KV, et al.: 2024 ESC Guidelines for the management of atrial fibrillation, European Heart Journal, 2024.
- Wiggins BS, Saseen JJ, Page RL II, et al.: Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association, Circulation, 2016.
- Libby P, Bonow RO, Mann DL, Tomaselli GF, Bhatt DL, Solomon SD: Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 12th Ed., Elsevier, 2022.
meritmedscript.comDr. Sidhartha Mullapudi
